NEW YORK ( TheStreet) --The 2012 BIO CEO & Investor Conference kicks off this morning here at the Waldorf-Astoria Hotel. The two-day conference, put on by BIO, the biotech industry's main lobbying group, typically spotlights small-cap biotech companies that are often shut out of investor conferences run by large investment banks. Biotech companies scheduled to present today include Celsion Pharmaceuticals ( CLSN), Cyclacel Pharmaceuticals ( CYCC), Chelsea Therapeutics ( CHTP), Navidea Biopharmaceuticals ( NAVB), Galena Biopharma ( GALE), Titan Pharmaceuticals ( TTNP) and Oxigene ( OXGN). Today's agenda also includes panel discussions on cancer clinical trials, the "beta amyloid debate" in Alzheimer's disease drug research and biotech financing. On Tuesday, biotech and drug presenters include Delcath Systems ( DCTH), Keryx Pharmaceuticals ( KERX), Oncothyreon ( ONTY), Acorda Therapeutics ( ACOR) and Idenix Pharmaceuticals ( IDIX). Gilead Sciences' ( GILD) President John Milligan will also be featured in a "fireside chat." To make it easier to follow the news, debate and conversations expected to flow from this years BIO CEO confab, feel free to check in periodically to this live blog that will aggregate all tweets using the #BIOCEO2012 hashtag. --Written by Adam Feuerstein in New York. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.